Philippines officials nix Sanofi's attempt to bring Dengvaxia back to market

sny
Sanofi fell short in an appeal against Philippine officials' decision to ban dengue vaccine Dengvaxia. (Sanofi on Flickr)

Sanofi has been through an ordeal with its Dengvaxia rollout in the Philippines, but earlier this month, it looked as if officials might reintroduce the dengue vaccine to battle a deadly outbreak. For now, though, that's off the table.

This week, the country’s Department of Health upheld an earlier decision that revoked Sanofi’s certificates of product registration based on the company’s failure to “submit post-approval requirements.” 

In this review, officials weren’t even looking at Dengvaxia’s efficacy. The decision “concerns Sanofi’s complete disregard of FDA regulations, which were precisely put in place by law to ensure safety,” health secretary Francisco Duque III said in a statement. Sanofi had filed an appeal in a bid to get the vaccine back on the market.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Officials aren’t fully closing the door on Dengvaxia, though. The agency said Sanofi may seek a new approval if it complies with the country’s laws. This time, though, Sanofi failed to live up to its post-marketing commitments, officials said.

RELATED: Philippine officials consider Sanofi's Dengvaxia—again—amid deadly outbreak 

The Philippines declared a “national dengue epidemic” this month amid an outbreak that has killed at least 622 people. Officials have tracked 146,062 cases from January to July 20, a 98% increase over the same period last year. 

The country was among the first to approve and launch Sanofi’s Dengvaxia, but after the company in 2017 reported the shot can cause more serious infections if given to people who haven’t had a prior infection, a scandal ensued. Officials quickly called off vaccinations and struck up investigations. Authorities later pulled the vaccine from the market completely. 

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.